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Background. We investigated the association between the reduction in the estimated glomerular filtration rate (eGFR) and the
prevalence of monoclonal gammopathy of undetermined significance (MGUS) in Korean males.Methods. We enrolled 723 healthy
Koreanmales. Serum creatinine concentration, serum electrophoresis, serum immunofixation, and the serum free light chain assay
were performed. We calculated delta eGFR per year (ΔeGFR/yr). The prevalence of MGUS was compared based on the ΔeGFR/yr
and age group. Results.Thirteen (1.8%) of 723 participants exhibited themonoclonal band on serum immunofixation. Prevalence of
MGUSby age groupwas 0.00% (0/172 for 40 years), 1.63% (6/367 for 60 years), and 3.80% (7/184 for>60 years).Themedian decrease
inΔeGFR/yrwas 5.3%.Theprevalence ofMGUS in participants in their 50swith>5.3%decline inΔeGFR/yrwas significantly higher
than those with <5.3% decrease in ΔeGFR/yr (3.16% versus 0.00%; 𝑃 = 0.049). The prevalence of MGUS in participants in their
50s with >5.3% decrease in ΔeGFR/yr was similar to that of healthy males in their 60s. Conclusion. Using the rate of reduction in
ΔeGFR/yr in healthy Korean males who had their serum creatinine level checked regularly may increase the MGUS detection rate
in clinical practice.
1. Introduction
Monoclonal gammopathy of undetermined significance
(MGUS) is the most common plasma cell disorder, and its
prevalence increases with age [1–4].The prevalence ofMGUS
is also affected by race and sex, but MGUS generally develops
in older people, African-Americans, and males with a slight
predominance [1–5]. In previous studies, the prevalence of
MGUS was 4.9% in Caucasian males > 60 years old [2] and
3.8% in Korean males > 65 years old [3].
Several studies of the prevalence of MGUS stratified by
age category in each race have been conducted. However, to
the best of our knowledge, none has reported the correlation
between the degree of estimated glomerular filtration rate
(eGFR) reduction and the prevalence of MGUS. And the
association between measurement of free kappa and lambda
light chains by the serum FLC assay and the prevalence of
MGUS has not been well documented either. Thus, in this
study we investigated the correlation between the degree of
egfr reduction andMGUS prevalence among Korean healthy
males.
2. Materials and Methods
2.1. Subjects. The study included Korean males over 40 years
old who visited the hospital for regular health checkups
between June 2011 and March 2012. A total of 723 males had
regular checkups during the period. According to the review
of the electronicmedical records, all of the study subjects have
not been diagnosed with MGUS previously. This study was
approved by the Institutional ReviewBoard ofASANMedical
Center (approval no. 2012-0065).
2.2. Specimen and Data Collection. After general blood
chemistry, the remaining 1mL of serum was collected in two
microtubes and stored at −70∘C. One of the two microtubes
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Table 1: Baseline demographic chracteristics of the study population stratified by age.
Variable 40–49 yrs 50–59 yrs ≥60 yrs All
𝑁 172 367 184 723
Age (yrs) 47.0 ± 1.7 54.3 ± 2.9 65.4 ± 5.2 55.4 ± 7.4
Interval of health checkup (days) 395.6 ± 97.3 394.5 ± 91.7 420.2 ± 113.4 401.3 ± 99.4
Current sCr (mg/dL) 0.989 ± 0.123 0.996 ± 0.155 1.015 ± 0.155 0.999 ± 0.148
Previous sCr (mg/dL) 0.943 ± 0.113 0.941 ± 0.117 0.968 ± 0.129 0.949 ± 0.120
Current eGFR (mL/min/1.73m2) 82.6 ± 11.5 80.2 ± 12.6 75.6 ± 12.8 79.6 ± 12.7
Previous GFR (mL/min/1.73m2) 87.7 ± 12.6 85.3 ± 11.9 79.8 ± 12.7 84.5 ± 12.6
ΔeGFR/yr (%) −5.1 ± 9.0 −5.6 ± 8.5 −4.7 ± 8.0 −5.3 ± 8.5
𝜅 FLC (mg/L) 9.77 (2.38–25.91) 10.76 (2.17–292.53) 11.54 (2.17–1,265.95) 11.10 (2.17–1,265.95)
𝜆 FLC (mg/L) 11.13 (6.38–30.31) 11.71 (2.51–34.71) 12.06 (2.51–34.71) 11.84 (2.51–34.71)
𝜅/𝜆 ratio 0.84 (0.19–1.99) 0.91 (0.33–44.26) 0.94 (0.33–156.68) 0.92 (0.19–156.68)
Data expressed as means ± standard deviation or medians (range).
Abbreviations: CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration; eGFR: estimated glomerular filtration rate; FLC: free light chain; MDRD:
Modification of Diet in Renal Disease; sCr: serum creatinine.
was used for serumprotein electrophoresis (sPEP) and serum
immunofixation electrophoresis (sIFE), while the other was
used for the serum free light chain (sFLC) assay. Electronic
medical records were used to collect participant data, such as
age, date of current health checkup, date of previous health
checkup, and current and previous serum creatinine levels.
2.3. Laboratory Tests. Serum creatinine levels of the partici-
pants during the study period weremeasured using a Toshiba
200-FR Neo (Toshiba Medical Systems Co., Tokyo, Japan)
instrument with the IDMS-traceable calibrator (c.f.a.s cali-
brator, Roche Diagnostics, Indianapolis, IN, USA). Previous
serum creatinine levels were measured using the Toshiba
200-FR Neo with the same IDMS-traceable calibrator. The
Hydrasys 2 (Sebia, Evry, France) instrument was used to
perform both sPEP and sIFE based on the manufacturer’s
instructions. The sIFE was performed to detect kappa and
lambda free light chains in sera.The sFLC assay was analyzed
using SPAplus (Binding Site, Birmingham, UK) instrument
with Freelite (Binding Site) reagents. Both kappa and lambda
free light chain concentrations were measured quantitatively
to calculate the kappa/lambda FLC ratio.The reference range
for the sFLC ratio was 0.26–1.65 [6].
2.4. Calculating eGFR and ΔeGFR. All participants were
Korean males. Their current and previous eGFR values
were calculated using the four-variable MDRD study equa-
tion (eGFR = 175 × standardized serum creatinine−1.154 ×
age−0.203). The delta eGFR (ΔeGFR, %) was calculated as the
difference between current eGFR and previous eGFR [100 ×
(current eGFR-previous eGFR)/previous eGFR], whereas the
annual rate of decline in eGFR [ΔeGFR/yr (%)] was deter-
mined as the difference between the follow-up and baseline
eGFR values, with this value divided by the time interval
[100 × (current eGFR-previous eGFR)/previous eGFR] ×
(365/Δdays).
2.5. Definition of MGUS. MGUS is defined as serum mon-
oclonal protein <3 g/dL, clonal bone marrow clonal plasma
cells <10%, and absence of end organ damage such as hyper-
calcemia, renal insufficiency, anemia, and bone lesions
(CRAB) that can be attributed to the plasma cell proliferation
disorder [7]. In this study,MGUS was defined as an absence
of CRAB symptoms and presence of monoclonal protein
confirmed by sIFE. The CRAB symptoms were identified
through review of the electronic medical records including
laboratory findings.
2.6. Statistical Analyses. The participants were grouped by
age (40, 50, and >60 years) andΔeGFR/yr (classified into two
groups by median ΔeGFR/yr). The prevalence of MGUS was
calculated for each group and the differences were analyzed
by the chi-square test or Fisher’s exact test. SPSS version 19.0
(SPSS, Inc., Chicago, IL, USA) was used for statistical analy-
ses. A 𝑃 value <0.05 was considered to indicate significance.
3. Results
3.1. Baseline Characteristics. Themean age of the participants
was 55.4 ± 7.4 years (range, 41–90 years) and the average
health checkup interval was 401.3 ± 99.4 days (range, 202–
768 days). The current serum creatinine level increased by
an average of 0.051 ± 0.089mg/dL from the previous serum
creatinine level. eGFR decreased by an annual average of 5.3±
8.5%, and 363 participants had ≥5.3% reduction. Median val-
ues of serum kappa FLC concentration, serum lambda FLC
concentration, and the serum kappa/lambda FLC ratio were
11.10mg/L, 11.84mg/L, and 0.92, respectively. The baseline
demographic chracteristics of the study population stratified
by age are summarized in Table 1.
3.2. sPEP, sIFE, and sFLC Assays. The monoclonal protein
was detected in 9 participants by sPEP, 13 by sIFE, and 21
by the sFLC ratio, respectively. Four participants had the
monoclonal protein in all three tests.Themonoclonal protein
was detected in 4 participants by only sIFE and in 17 by only
the sFLC assay.

































Figure 1: Prevalence of monoclonal gammopathy of undetermined significance in Korean males based on delta estimated glomerular
filtration rate and age.
3.3. Prevalence of MGUS. Thirteen (1.80%) of the seven
hundred and twenty-three participants had the monoclonal
band on sIFE. The prevalence of MGUS by age group was
0.00% (0/172, 40 years of age), 1.63% (6/367, 50 years of age),
and 3.80% (7/184, ≥60 years of age) (Table 2).
The MGUS prevalence in the group with ≥5.3% decline
in ΔeGFR/yr was 2.75% (10/363), almost threefold that in
the other groups (0.83%, 3/360); however, the difference was
not significant (𝑃 = 0.089). In an age-stratified analyses, the
prevalence of MGUS in 50s with ≥5.3% decline in ΔeGFR/yr
group was significantly higher than those with <5.3% decline
in ΔeGFR/yr group (3.16% versus 0.00%; 𝑃 = 0.049)
(Figure 1). In the 60 years of age or older group, however, the
prevalence of MGUS showed no significant difference based
on ΔeGFR/yr (4.71% versus 3.03%; 𝑃 = 0.438) (Figure 1).
The MGUS prevalence in participants with kappa or
lambda FLC concentrations higher than the reference value
on sFLCwas 10.91% (6/55), significantly higher than the 1.05%
(7/668) in those with a normal serum kappa and lambda FLC
concentration.
4. Discussion
We investigated the association between ΔeGFR/yr and
prevalence of MGUS in healthy Korean males aged over 40
years. Our results showed that MGUS prevalence values in
Korean men in their 40 (0.00%), 50 (1.63%), and >60 years of
age (3.80%) were similar to MGUS values for Japanese males
in their 40 (1.2%), 50 (2.7%), and >60 years of age (4.3%) and
Chinese men 50–65 years (1.2%) [8, 9]. To date, the MGUS
prevalence in Koreans has been determined only in elderly
people >65 years [3]. In the present study, the prevalence of
MGUS in participants>60 years was 3.80%whichwas similar
to those obtained fromelderlyKoreanmale aged over 65 years
(3.8%) [3].
By definition of MGUS, there is no renal insufficiency.
However, excess serum free light chains and intact im-
munoglobulins that exceed the metabolic ability of kid-
ney function in patients with MGUS can accumulate in
the kidney, resulting in subclinical renal insufficiency such as
a decline in GFR [10, 11]. On the basis of above consideration,
we had assumed that the prevalence of MGUS may be
higher in patients with markedly reduction of GFR. And
the GFR decline may occur within reference range of serum
creatinine. In our study, although the prevalence of MGUS
in all participants was not significantly different based on
the ΔeGFR, a statistically significant difference was found in
the group in their 50s. The difference between the 50s group
and those >60 can be partially explained that MGUS is not
always a premalignant lesion. Our study indicated that there
was apparent association between the MGUS and ΔeGFR;
however, a large-scale cohort study is needed to reach the
statistical significance.
According to the current MGUS management guideline,
MGUS does not require aggressive treatment [12]. However,
MGUS is an obvious premalignant lesion that requires careful
observation because it progresses to multiple myeloma or
other plasma cell-related disorders in some patients [12–15].
In this study, the MGUS prevalence in the group with ≥5.3%
decline in ΔeGFR/yr was almost threefold that in the other
groups. The prevalence of MGUS in participants in their 50s
with a high rate of decrease in ΔeGFR/yr was 3.16%, which
was similar to that in the group in their 60s. As 10–20% of
those with MGUS in this group are likely to develop multiple
myeloma or diverse malignant plasma cell disorders when
they reach 60–70 years of age, early detection of MGUS in
50s should be considered.
Measurement of serum creatinine level is included in
the National Health Screening Program organized by the
National Health Insurance Service for Koreans who are
required to undergo a regular health checkup every year or
2 years. And the ΔeGFR can be calculated from those data.
We thought that addition of screening formonoclonal protein
in those whose ΔeGFR/yr shows a marked reduction may
increase the MGUS diagnostic rate.
In this study, we observed 9 samples of false-negative
results for sFLC assay based on the sIFE findings. We
thought that possible sources of false-negative results of sFLC
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Table 2: Prevalence of monoclonal gammopathy of undetermined significance (MGUS) in Korean males.
Age (yrs) Total number of patients Number of patients with MGUS Prevalence of MGUS
40–49 172 0 0.00%
50–59 367 6 1.63%
≥60 184 7 3.80%
All 723 13 1.80%
assay were antigen excess [16], FLC polymerization [17], and
polyclonal FLC elevation [18]. On the other hand, sFLC assay
demonstrated false-positive results for 17 samples based on
the sIFE findings. Seventeen participants were normal on
the sIFE and sPEP tests but had an abnormal sFLC ratio.
Among them, 15 participants showed kappa clonality which
means that their sFLC ratio showed more than 1.65 and
the remaining 2 participants demonstrated lambda clonality
which means that their sFLC ratio is less than 0.26 (data
not shown). It has been well documented that sFLC assay
could detect monoclonal protein more sensitive than sPEP
and sIFE assay [6, 19]. So it is not clear whether 17 samples
are true false-positive results. These 17 participants may have
monoclonal protein in their sera. So we thought that they
need to be monitored to identify monoclonal protein.
In conclusion, the prevalence ofMGUS in healthy Korean
males in their 50s with a decrease in ΔeGFR/yr of ≥5.3% was
significantly higher than those with a decrease in ΔeGFR/yr
of <5.3%. Additionally, the prevalence of MGUS was similar
to that of healthy Korean males in their 60s. Using ΔeGFR/yr
in healthy Korean males whose serum creatinine level is
checked regularly may facilitate early detection of MGUS.
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